SCHEMBL10189675

SCHEMBL10189675

COc1ccc(-c2cnnn2-c2cc(OC)c(OC)c(OC)c2)cc1O[PH](=O)O

nearest known ligand 0.68

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
LMNA P02545 2/20 0.48
MAPT P10636 3/20 0.47
HPGD P15428 3/20 0.47
MEN1 O00255 1/20 0.47
TP53 P04637 1/20 0.47
KMT2A Q03164 1/20 0.47
NPSR1 Q6W5P4 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
TSHR P16473 1/20 0.46
MAPK1 P28482 1/20 0.46
CYP2C19 P33261 1/20 0.46
KDM4E B2RXH2 1/20 0.41
RECQL P46063 1/20 0.41
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL411930 0.82 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2LMNAMAPTHPGD
SCHEMBL411526 0.82 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2LMNAMAPTHPGD
SCHEMBL17225916 0.82 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2LMNAMAPTHPGD
SCHEMBL410417 0.81 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2LMNAMAPTHPGD
SCHEMBL411990 0.81 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2LMNA
SCHEMBL410418 0.80 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2LMNAMAPTHPGD
SCHEMBL410809 0.80 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2LMNAMAPTHPGD
SCHEMBL410351 0.79 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2LMNAMAPTHPGD
SCHEMBL412289 0.79 ALDH1A1 (0.63) ALDH1A1SMN1; SMN2
SCHEMBL10241455 0.79 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2LMNAMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9175022-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2015-11-03 US disclosed
US-8501790-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2013-08-06 US disclosed
US-20120022118-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP. 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022118-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS RB1, MKI67, MAPRE1 ALDH1A1 1872/4885SMN1; SMN2 3188/4885LMNA 2274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.